NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 358 filers reported holding NOVOCURE LTD in Q4 2020. The put-call ratio across all filers is 0.69 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $738,000 | -59.9% | 9,718 | -63.3% | 0.04% | -49.4% |
| Q2 2022 | $1,840,000 | +217.2% | 26,480 | +278.6% | 0.09% | +178.1% |
| Q1 2022 | $580,000 | -70.2% | 6,995 | -73.0% | 0.03% | -55.6% |
| Q4 2021 | $1,945,000 | +58.0% | 25,902 | +144.4% | 0.07% | +12.5% |
| Q3 2021 | $1,231,000 | +67.5% | 10,600 | +220.0% | 0.06% | +100.0% |
| Q2 2021 | $735,000 | -28.6% | 3,312 | -57.5% | 0.03% | -43.9% |
| Q1 2021 | $1,030,000 | +302.3% | 7,789 | +238.7% | 0.06% | +103.6% |
| Q3 2020 | $256,000 | -18.5% | 2,300 | -56.6% | 0.03% | -46.2% |
| Q2 2020 | $314,000 | -54.8% | 5,300 | -48.5% | 0.05% | -38.1% |
| Q1 2020 | $694,000 | +87.1% | 10,300 | +134.1% | 0.08% | +180.0% |
| Q4 2019 | $371,000 | -71.3% | 4,400 | -74.6% | 0.03% | -62.0% |
| Q3 2019 | $1,294,000 | +82.8% | 17,300 | +54.5% | 0.08% | +29.5% |
| Q2 2019 | $708,000 | – | 11,200 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 350,884 | $26,344,000 | 8.01% |
| HARTLINE INVESTMENT CORP/ | 318,109 | $23,884,000 | 3.27% |
| Deep Track Capital, LP | 550,000 | $41,294,000 | 2.92% |
| MORGAN JESS S & CO INC | 43,975 | $3,302,000 | 2.03% |
| Taylor Frigon Capital Management LLC | 46,376 | $3,482,000 | 1.09% |
| Darsana Capital Partners LP | 258,937 | $19,441,000 | 0.90% |
| Private Harbour Investment Management & Counsel, LLC | 13,562 | $1,018,000 | 0.81% |
| Rhenman & Partners Asset Management AB | 120,387 | $9,610,000 | 0.64% |
| COURAGE CAPITAL MANAGEMENT LLC | 10,000 | $751,000 | 0.50% |
| Baillie Gifford | 9,615,168 | $721,906,000 | 0.40% |